Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis (Q39612127)

https://doi.org/10.3892/or.2023.8519

13 September 2017

1 reference

29 December 2023

https://retractionwatch.com/2023/01/11/japanese-university-asks-surgeon-to-retract-eight-fraudulent-papers/

title

Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis (English)

1 reference

oral squamous cell carcinoma

13 September 2017

main subject

1 reference

Sayaka Yoshiba

1

1 reference

13 September 2017

Masayasu Iwase

2

1 reference

13 September 2017

Sayaka Kurihara

3

1 reference

13 September 2017

Makiko Uchida

4

1 reference

13 September 2017

Yuji Kurihara

5

1 reference

13 September 2017

Hitoshi Watanabe

6

1 reference

13 September 2017

Satoru Shintani

7

1 reference

13 September 2017

publication date

28 December 2010

1 reference

13 September 2017

1 reference

13 September 2017

volume

25

1 reference

13 September 2017

issue

3

1 reference

13 September 2017

page(s)

645-652

1 reference

MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L).

13 September 2017

cites work

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Regulation of apoptosis proteins in cancer cells by ubiquitin

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

TRAIL and apoptosis induction by TNF-family death receptors.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Tumor suppressor XIAP-Associated factor 1 (XAF1) cooperates with tumor necrosis factor-related apoptosis-inducing ligand to suppress colon cancer growth and trigger tumor regression

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Programmed cell death pathways and current antitumor targets

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Time sequence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin treatment is responsible for a complex pattern of synergistic cytotoxicity

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Enhanced susceptibility of oral squamous cell carcinoma cell lines to FAS-mediated apoptosis by cisplatin and 5-fluorouracil

2 references

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/IJC.11239

Targeting death-inducing receptors in cancer therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

The TRAIL apoptotic pathway in cancer onset, progression and therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Apoptotic pathways: paper wraps stone blunts scissors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Deadly encounter: ubiquitin meets apoptosis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Increased expression of cFLIP(L) in colonic adenocarcinoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

TRAIL and its receptors as targets for cancer therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.3892/OR.2010.1127

Identifiers

DOI

10.3892/OR.2010.1127

1 reference

13 September 2017

1 reference